OverviewSuggest Edit

BioMarin develops and provides innovative biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® for mucopolysaccharidosis VI; Aldurazyme® for mucopolysaccharidosis I; and Kuvan® Tablets, for phenylketonuria.

TypePublic
Founded1997
HQSan Rafael, CA, US
Websitebiomarin.com
Employee Ratings3.9
Overall CultureA-

Latest Updates

Employees (est.) (Feb 2020)3,001(+6%)
Revenue (FY, 2020)$1.9 B(+10%)
Share Price (Sept 2021)$76.2(-2%)
Cybersecurity ratingAMore

Key People/Management at BioMarin Pharmaceutical

Philip Lo Scalzo

Philip Lo Scalzo

Senior Vice President, Chief Compliance Officer
Jean-Jacques Bienaimé

Jean-Jacques Bienaimé

Chairman and Chief Executive Officer
Elizabeth McKee Anderson

Elizabeth McKee Anderson

Director
Robert A. Baffi

Robert A. Baffi

Executive Vice President, Technical Operations
G. Eric Davis

G. Eric Davis

Executive Vice President, General Counsel and Secretary
Willard H. Dere

Willard H. Dere

Director
Show more

BioMarin Pharmaceutical Office Locations

BioMarin Pharmaceutical has offices in San Rafael, Chicago, Columbus, Denver and in 26 other locations
San Rafael, CA, US (HQ)
770 Lindaro St
Chicago, IL, US
Chicago, IL, USA
Columbus, OH, US
Columbus, OH, USA
Denver, CO, US
Denver, CO, USA
Indianapolis, IN, US
Indianapolis, IN, USA
Lincoln, NE, US
Lincoln, NE, USA
Show all (34)

BioMarin Pharmaceutical Financials and Metrics

BioMarin Pharmaceutical Revenue

Embed Graph
View revenue for all periods
BioMarin Pharmaceutical's revenue was reported to be $1.86 b in FY, 2020
USD

Revenue (Q1, 2021)

486.0m

Gross profit (Q1, 2021)

365.9m

Gross profit margin (Q1, 2021), %

75.3%

Net income (Q1, 2021)

17.4m

EBIT (Q1, 2021)

25.1m

Market capitalization (14-Sept-2021)

13.9b

Closing stock price (14-Sept-2021)

76.2

Cash (31-Mar-2021)

667.3m

EV

14.3b
BioMarin Pharmaceutical's current market capitalization is $13.9 b.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

376.3m441.4m500.7m548.5m751.0m889.9m1.1b1.3b1.5b1.7b1.9b

Revenue growth, %

37%18%26%

Cost of goods sold

70.3m84.0m91.8m95.7m129.8m152.0m209.6m241.8m315.3m359.5m524.3m

Gross profit

306.0m357.3m408.9m452.7m621.3m737.9m907.2m1.1b1.2b1.3b1.3b
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

92.0m97.8m109.5m110.6m113.4m116.6m124.0m128.1m127.9m136.8m136.9m151.6m191.8m176.8m203.3m250.5m208.9m236.7m300.0m279.9m303.7m317.4m334.1m373.4m372.8m391.7m400.7m387.8m461.1m502.1m419.0m460.7m486.0m

Cost of goods sold

14.4m18.0m20.8m19.3m22.4m17.1m23.6m24.6m20.5m22.6m28.1m22.8m31.2m29.9m32.8m39.9m36.7m43.1m51.6m50.7m50.0m56.3m59.5m82.3m79.0m78.9m89.2m77.4m96.9m111.4m120.2m

Gross profit

77.5m79.7m88.7m91.4m91.0m99.5m100.4m103.5m107.4m114.2m108.8m128.7m160.6m146.9m170.5m210.6m172.2m193.6m248.4m229.2m253.7m261.1m274.7m291.1m293.8m312.8m311.6m310.3m364.1m390.7m365.9m

Gross profit Margin, %

84%82%81%83%80%85%81%81%84%84%80%85%84%83%84%84%82%82%83%82%84%82%82%78%79%80%78%80%79%78%75%
USDQ2, 2010

Financial Leverage

2.7 x
Show all financial metrics

BioMarin Pharmaceutical Operating Metrics

FY, 2016

Patent Applications

426

Patents Issued

1.17 k

Phase I/II Trials Products

2

Phase III Trials Products

2
Show all operating metrics

BioMarin Pharmaceutical Revenue Breakdown

Embed Graph

BioMarin Pharmaceutical revenue breakdown by geographic segment: 45.5% from United States, 22.7% from Europe, 13.3% from Latin America and 18.4% from Rest of the World

BioMarin Pharmaceutical Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

BioMarin Pharmaceutical Online and Social Media Presence

Embed Graph

BioMarin Pharmaceutical Company Culture

  • Overall Culture

    A-

    75/100

  • CEO Rating

    A

    77/100

  • Compensation

    B

    76/100

  • Diversity

    A-

    79/100

Learn more on Comparably

BioMarin Pharmaceutical News and Updates

Should You Buy BioMarin Pharmaceutical Stock At $78?

We believe that BioMarin Pharmaceutical stock is a good buying opportunity at the present time. BMRN stock trades near $78 currently and it is, in fact, down 19% from its pre-Covid high of around $97 in March 2020 – before the coronavirus pandemic hit the world. BMRN stock has had a volatile ride...

BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) and certain of its officers, on behalf of share…

BIOMARIN 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN

NEW ORLEANS, Nov. 23, 2020 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until November 24, 2020 to file lead plaintiff applications in a securities class action lawsuit...

BMRN FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical Inc. Investors of Important Tuesday Deadline in Securities Class Action – BMRN

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”), of the important November 24, 2020 lead …

BioMarin Pharmaceutical, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm

Investors with losses are encouraged to contact the firm before November 24, 2020; click here to submit trade information

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - BMRN

NEW YORK, Nov. 18, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020, inclusive (the "Class Period"), of the important November 24, 2020...
Show more

BioMarin Pharmaceutical Frequently Asked Questions

  • When was BioMarin Pharmaceutical founded?

    BioMarin Pharmaceutical was founded in 1997.

  • Who are BioMarin Pharmaceutical key executives?

    BioMarin Pharmaceutical's key executives are Philip Lo Scalzo, Jean-Jacques Bienaimé and Elizabeth McKee Anderson.

  • How many employees does BioMarin Pharmaceutical have?

    BioMarin Pharmaceutical has 3,001 employees.

  • What is BioMarin Pharmaceutical revenue?

    Latest BioMarin Pharmaceutical annual revenue is $1.9 b.

  • What is BioMarin Pharmaceutical revenue per employee?

    Latest BioMarin Pharmaceutical revenue per employee is $619.9 k.

  • Who are BioMarin Pharmaceutical competitors?

    Competitors of BioMarin Pharmaceutical include Alembic Pharmaceuticals, Livzon Pharmaceutical Group and Cipla.

  • Where is BioMarin Pharmaceutical headquarters?

    BioMarin Pharmaceutical headquarters is located at 770 Lindaro St, San Rafael.

  • Where are BioMarin Pharmaceutical offices?

    BioMarin Pharmaceutical has offices in San Rafael, Chicago, Columbus, Denver and in 26 other locations.

  • How many offices does BioMarin Pharmaceutical have?

    BioMarin Pharmaceutical has 34 offices.